Initiative will deploy predictive big data analytics to analyze patient data from landmark CoMMpass Study™ to speed drug discovery and development for patients with multiple myeloma
CAMBRIDGE, Mass. & NORWALK, Conn.–(BUSINESS WIRE)–GNS Healthcare (GNS), a leading provider of analytics solutions for driving personalized interventions that improve population health, and the Multiple Myeloma Research Foundation (MMRF), a leader in accelerating the development of breakthrough multiple myeloma therapies, today announced a collaboration to speed the discovery of innovative treatments for patients with multiple myeloma. The effort will combine the unprecedented genomic and clinical data from the MMRF’s landmark CoMMpass Study™ with revolutionary GNS machine learning platforms and rapid computer simulations. The work supports the development of computer models of myeloma disease that may uncover novel molecular pathways that can prevent progression of disease and address the unmet treatment needs of patients with multiple myeloma.
“This work embodies the transformative role for big data analytics to uncover specific treatment protocols that have a much better chance of success for individual patients,”